SUMMARY
Strict regulation of signaling by receptor tyrosine kinases (RTKs) is essential for normal biological processes, and disruption of this regulation can lead to tumor initiation and progression. Signal duration by the Met RTK is mediated in part by the E3 ligase Cbl. Cbl is recruited to Met upon kinase activation and promotes ubiquitination, trafficking, and degradation of the receptor. The Met RTK has been demonstrated to play a role in various types of cancer. Here, we show that Met-dependent loss of Cbl protein in MET-amplified gastric cancer cell lines represents another mechanism contributing to signal dysregulation. Loss of Cbl protein is dependent on Met kinase activity and is partially rescued with a proteasome inhibitor, lactacystin. Moreover, Cbl loss not only uncouples Met from Cbl-mediated negative regulation, but also releases other Cbl-targets, such as the EGF receptor, from Cbl-mediated signal attenuation. Thus, Met-dependent Cbl loss may also promote cross-talk through indirect enhancement of EGFR signaling.
Receptor tyrosine kinases (RTKs) are key components of signaling cascades that promote cellular proliferation and differentiation. These processes are essential for normal human embryogenesis and homeostasis, and when dysregulated, can drive the unconstrained cell growth and invasiveness characteristic of many human cancers.
The Met RTK was initially identified as an oncogenic fusion protein (Tpr-Met) following treatment of human osteogenic sarcoma (HOS) cell line with the carcinogen, N-methyl-N'-nitronitrosoguanidine (1, 2) . Met was subsequently identified as the receptor for Hepatocyte Growth Factor (HGF) or scatter factor (SF) (3, 4) . HGF-Met signaling promotes scatter and an invasive morphogenic response in epithelial cells in cell culture (5) , and is required during embryogenesis for development of the placenta, liver, kidney, and neuronal and skeletal muscle (6) . In the adult, the HGF-Met signaling axis is involved in wound healing and liver regeneration (7, 8) . Tight regulation of Met signaling is required for many of these processes, and dysregulation of the Met signaling axis has been implicated in various human cancers (www.vai.org/met).
Several mechanisms leading to dysregulation of Met in cancer have been identified. These include autocrine/paracrine activation, Met overexpression, genomic amplification, point mutation and alternative splicing (9) .
MET amplification occurs frequently in gastric cancers (10) , and to a lesser extent in non-small cell lung cancer (NSCLC) and glioblastomas (11) (12) (13) (14) .
Loss of negative regulation represents an additional mechanism through which oncogenic activation of Met can occur (15) . Negative regulation of Met is primarily mediated through the Cbl E3 ligase. The Cbl family of E3 ligases consists of 3 mammalian homologues: c-Cbl, 2 Cbl-b, and Cbl-3 (16-18). These cytoplasmic proteins are conserved in their N-terminal halves and consist of a tyrosine kinase binding (TKB) domain, a linker region, and a RING domain, the latter of which is required for functional E3 ligase activity (reviewed in (19)). The Cterminal portions are less well conserved, and include a proline-rich region and a UBA domain (c-Cbl and Cbl-b) (19). The UBA domains of both c-Cbl and Cbl-b facilitate dimerization, but only the Cbl-b UBA domain is able to bind ubiquitin (20) (21) (22) . The presence of key tyrosine residues as well as proline-rich regions allows for Cbl proteins to also function as scaffolds capable of recruiting a number of SH2-and SH3-domain containing proteins (19) .
Both c-Cbl and Cbl-b act as E3 ligases and ubiquitinate their target substrates (reviewed in (23). Overlap of c-Cbl and Cbl-b function is evident as CBL -/-or CBLB -/-mice are both viable, but mice deficient in both are embryonic lethal (23, 24) . Similarly, in osteoclasts, depletion of both proteins are required to disrupt the microtubule network and induce apoptosis (25). However, differences in c-Cbl and Cbl-b function exist. c-Cbl and Cbl-b are recruited to EGFR at temporally distinct periods, subsequent to EGF stimulation, where c-Cbl is recruited early (5-15 min), and Cbl-b is recruited by 1h poststimulation (26). Moreover, whereas c-Cbl or Cbl-b ubiquitination of its substrates, such as RTKs, primarily promotes degradation, Cbl-b targeted ubiquitination of some substrates, such as the p85 subunit of PI3-kinase, impinges on protein-protein interactions, but leave overall protein levels unchanged (reviewed in (23)), highlighting potential distinct roles of Cbl proteins.
Upon Met kinase activation, intracellular tyrosine residues are phosphorylated, creating docking sites for a number of downstream signaling molecules. Phosphorylation of Y1003 in the Met juxtamembrane domain allows for direct recruitment of Cbl, through the Cbl TKB domain (27) . Cbl recruitment to Met is also indirectly mediated through Grb2, (5, 27, 28) . Upon Cbl recruitment, Met is ubiquitinated (27). This is required for efficient recognition of Met during trafficking and subsequent degradation in the lysosome (29, 30) . Uncoupling of Met from Cbl, through substitution of the Cbl binding site Y1003 with a phenylalanine residue, results in a Met receptor that is poorly ubiquitinated, exhibits enhanced stability, prolonged phosphorylation and is transforming in vitro and in vivo (29) . Moreover, Tpr-Met, a truncated, constitutively active, and cytoplasmic variant of Met, lacks the juxtamembrane region containing Y1003, does not recruit the Cbl TKB domain, is not ubiquitinated, and fails to enter the endocytic degradative pathway (31) . This escape from entry into the degradative pathway may represent a common mechanism that contributes to oncogenic activation of many RTKs following chromosomal reorganization (15) The importance of Cbl-mediated negative regulation of Met as a mechanism counteracting tumorigenesis is further emphasized by the identification of naturally occurring Met variants in cancers that lack the Cbl binding site. Alternatively spliced mutants of Met that result in the excision of exon 14 containing the Cbl TKB domain binding site (Y1003), have been identified in both non-small cell lung cancer cell lines and adenocarcinoma lung tumors (32) (33) (34) . These Met variants show enhanced stability and prolonged signaling and oncogenic capacity (33) . In addition, the gastric cancer cell line Hs746T amplifies MET with a mutation, which results in the loss of exon 14 (35) . Hence, loss of negative regulation by Cbl may be selected for even when MET is amplified.
Here, we show that conditions where MET is amplified in human gastric cancers, leads to loss of Cbl protein. This reflects another mechanism through which Met is able to uncouple from Cbl-dependent negative regulation. Moreover, a loss of Cbl would not only enhance signaling by Met, but has the capability to dysregulate signaling by other Cbl targets, such as the EGFR. This represents a mechanism of RTK crosstalk in human tumors, whereby Cbl loss is dependent on Met kinase activity.
Cruz Biotechnology (Santa Cruz, CA). Met (AF276) and c-Cbl antibodies used for immunofluorescence were obtained from R&D Systems (Minneapolis, MN) and Epitomics Inc (Burlingame, CA). Actin and tubulin antibodies were obtained from Sigma-Adrich (Oakville, ON, Canada).
Phospho-specific Met tyrosine 1234/35, EGFR tyrosine Y992, general phosphotyrosine pY100, K48-linked poly ubiquitin (D9D5), and total EGFR antibodies were purchased from Cell Signaling Technology (Mississauga, ON, Canada). HA.11 monoclonal and phospho-Src tyrosine 418 antibodies were obtained from Covance (Berkeley, CA) and Invitrogen (Burlington, Ontario, Canada) respectively.
Beta-catenin antibody was purchased from BD Biosciences (Mississauga, ON, Canada)
HGF was a generous gift from Genentech (San Francisco, CA) and EGF purchased from Roche Diagnostics (Laval, Quebec, Canada). Concanamycin, Lactacystin and PP2 were purchased from EMD Chemicals (Gibbstown, NJ) and utilized at final concentrations of 0.1µM, 10µM, and 10µM respectively. Met inhibitor (PHA-665752) was a kind gift from Pfizer (Final concentration 0.1µM). Cell culture and Transient Transfections -HEK 293, Okajima, and MKN45 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). Snu-5 and KATO II cell lines were a kind gift from Dr. Daniel Haber and cultured in RPMI supplemented with 10% FBS. Transient transfections with HEK 293 cells were performed using Lipofectamine Plus reagent, according to the manufacturer's protocol (Invitrogen). Immunoprecipitation and Western Blotting -HEK 293, Okajima, MKN45, Snu-5, and KATO II cells were harvested in TGH lysis buffer (50mM HEPES, pH7.5; 150mM NaCl, 1.5mM MgCl 2 , 1mM EGTA, 1% Triton X-100, 10% glycerol, 1mM phenylmethylsulfonyl fluoride, 1mM sodium fluoride, 1mM sodium vanadate, 10µg/mL aprotinin, and 10µg/mL leupeptin). HEK293 transfections were harvested 48h posttransfection.
Lysates were incubated with antibody for 1h at 4°C with gentle rotation followed by 1h incubation with protein A-or GSepharose beads.
Captured proteins were collected by washing three times in TGH lysis buffer, eluted by boiling in SDS sample buffer, resolved by SDS-PAGE, and transferred to a nitrocellulose membrane. Membranes were blocked in 3% bovine serum albumin (BSA) in TBST (10mM Tris, pH8.0, 150mM NaCl, 2.5mM EDTA, 0.1% Tween 20) for 1h and incubated with primary antibodies in TBST overnight at 4°C. Membranes were then incubated with secondary antibodies in TBST for 1h. After three washes with TBST, bound proteins were visualized with an ECL detection kit (Amersham Biosciences).
For western blot analysis of c-Cbl and Cbl-b ubiquitination, cells were harvested in 150µL of denaturing TSD lysis buffer (50mM Tris-HCl (pH7.5), 1% SDS, 5mM DTT, 50µM MG132, 50mM N-ethylmaleimide, 1mM phenylmethylsulfonyl fluoride, 1mM sodium fluoride, 1mM sodium vanadate, 10µg/mL aprotinin, and 10µg/mL leupeptin). Lysates were boiled at 99°C for 5 min. and then pelleted in a microcentrifuge at 10 000rpm for 5 min. One hundred microliters of supernatant was then diluted to a final concentration of 0.1% SDS with TNESV buffer (50mM Tris-HCl (pH 7.5), 1% NP40, 100mM NaCl, 2mM EDTA, 10mM Nethylmaleimide, 1mM phenylmethylsulfonyl fluoride, 1mM sodium fluoride, 1mM sodium vanadate, 10µg/mL aprotinin, and 10µg/mL leupeptin). Immunoprecipitations were performed as described above but with TNESV buffer used in place of TGH lysis buffer.
For blots that required quantitation, membranes were blocked with Li-COR blocking buffer (Li-COR Biosciences), incubated with primary antibodies as described above, followed by incubation with infrared (IR)-conjugated secondary antibodies prior to detection and analysis on the Odyssey IR Imaging System (Li-COR Biosciences). siRNA -MKN45 or KATO II cells were plated at a confluency of 3x10 5 cells per well in a 6-well dish and transiently transfected in suspension with 20nM human MET on-Target Plus SMARTpool siRNA, 50nM human CBL siGENOME SMARTpool siRNA, 50nM human CBLB siGENOME SMARTpool siRNA, or equal concentration of scrambled control siRNA purchased from Dharmacon (Lafayette, CO) with Polyethylenimine (PEI) (Sigma-Aldrich, Oakville, ON, Canada). PEI was utilized at a final concentration of 3.75µg/mL. 48h after initial transfection, cells were re-transfected as previously described. Cells were then lysed 72h after initial transfection. Quantitative analysis of knockdown was assessed using Li-Cor Odyssey Infrared Imaging System as previously described. Quantitative Real-time PCR -Total cellular RNA was extracted using TRIzol reagent (Invitrogen) following the manufacturer's protocol. 800ng of RNA was reverse transcribed and amplified as previously described (29) . The 60S acidic ribosomal protein P0 (RPLP0), TATA-box-binding protein (TBP), Splicing factor, arginine/serine-rich 4 (SFRS4), and actin (ACTB) were used with geNorm software (37) 5 on glass coverslips (Bellco Glass Inc., Vineland, NJ) in 24-well plates (Nalgene Nunc, Rochester, NY). Forty-eight hours later, cells were washed once with PBS and then fixed with 2% paraformaldehyde (Fisher Scientific) in PBS for 20 min, followed by washing 3x in PBS. Residual paraformaldehyde was removed with three 5-min washes with 100 mM glycine in PBS. Cells were permeabilized with 0.2% Triton X-100/PBS and blocked for 30 min with blocking buffer (2% bovine serum albumin, 0.2% Triton X-100, 0.05% Tween 20, PBS). Coverslips were incubated with primary and secondary antibodies diluted in blocking buffer for 1 h and 40 min, respectively, at room temperature, and nuclei were counterstained with 4',6-diamidino-2-phenylindole. Coverslips were mounted with immu-mount (Thermo-Shandon, Pittsburgh, PA). Confocal images were taken using a Zeiss 510 Meta laser scanning confocal microscope (Carl Zeiss, Canada Ltd., Toronto, Ontario, Canada) with 100x objective. Image analysis was carried out using the LSM 5 image browser (Empix Imaging, Mississauga, Ontario, Canada). Colocalization Studies -Quantification of colocalization between Met and c-Cbl or Met and Cbl-b was performed using MetaMorph software for object-based colocalization measurements. Results were logged into Excel for analysis.
RESULTS

Cbl protein levels are elevated following inhibition of the Met kinase -
To establish if amplification of MET, in the Okajima, MKN45, Snu-5 and KATO II gastric cancer cell lines leads to constitutive activation of Met protein (10) , proteins from whole cell lysates were immunoblotted with Met and phospho-Met antibodies ( Fig. 1A-B) .
The phospho-Met antibody is specific for the tyrosines 1234 and 1235 in the activation loop of the kinase domain. High levels of Met and phospho-Met were observed in all of the cell lines tested.
To examine the status of Cbl proteins, lysates were immunoblotted with antibodies raised to the C-terminal regions of c-Cbl and Cblb. Whereas the c-Cbl antibody is selective for immunoprecipitation and immunoblotting of cCbl (Supplemental Fig. 1 ), some weak crossreactivity of the Cbl-b antibody with c-Cbl is observed, when c-Cbl is overexpressed in transient transfections (Supplemental Fig. 1 ). However, in the gastric cancer cell lines used, the Cbl-b antibody only detects Cbl-b, as established by the differences in molecular weight of c-Cbl (110kDa) when compared to Cbl-b (125kDa).
Immunoblotting with c-Cbl and Cbl-b antibodies demonstrate low levels of c-Cbl protein in all gastric cancer cell lines tested and variable levels of Cbl-b (Fig. 1A-B) . Interestingly, when Met kinase activity was inhibited with a small molecule Met kinase inhibitor (0.1 µM PHA-665752) (38) for 4, 8, or 16 hours, a pronounced increase in c-Cbl protein levels was observed in all cell lines and a moderate increase in Cbl-b levels was observed in two of the four cell lines (Snu-5 and KATO II) (Fig. 1A-B) . PHA-665752 is a small-molecule inhibitor that specifically targets Met, and inhibition of unrelated kinases only occurs at an IC 50 >2.5µM (38) . Quantitation of c-Cbl and Cbl-b protein levels from three experimental replicates reveals an inverse correlation between Met kinase activity and c-Cbl or Cbl-b levels in each cell line (Supplemental Fig. 2) .
To determine whether the change in Cbl protein levels, upon the addition of Met inhibitor, occurs through enhanced transcription, RNA from cells treated or not with Met inhibitor was isolated, reverse transcribed, and c-Cbl and Cbl-b levels determined using quantitative real-time PCR. At 16h post-treatment with Met inhibitor, a time where c-Cbl protein levels are maximally elevated, no significant increases in c-Cbl mRNA were observed (Fig. 1C-D) , when compared to the DMSO control. Hence, differences in Cbl protein level upon Met inhibitor treatment are not due to increase of CBL transcription.
To confirm that the increase in Cbl protein level is Met-dependent, and not due to off-target effects of the inhibitor, knockdown of Met protein was executed with siRNA in KATO II cells (Fig. 1E) . Upon depletion of Met protein, c-Cbl levels increase (Fig. 1E) , confirming the dependence of Cbl protein loss on Met.
As c-Cbl and Cbl-b can hetero-dimerize (21,22), we assessed whether this may play a role in their stability. In order to address whether Cbl-b influences c-Cbl stability and vice versa, cCbl or Cbl-b protein levels were depleted with targeted siRNA. Neither Cbl-b nor c-Cbl knockdown significantly altered steady-state levels stability of the other protein (Supplemental Fig. 3 ).
Cbl Levels are Independent of Src kinase activity -Overexpression of activated Src kinase has been shown to lead to a decrease in Cbl protein levels (39) . Src phosphorylation has also been demonstrated downstream of activated Met kinase (40) . To test if Met-dependent Cbl loss requires Src, cells were treated with the Src inhibitor PP2 (10µM), the Met inhibitor (0.1µM PHA-665752), or both. In gastric cancer cells with amplified MET, Src kinase is constitutively active, as evident by the basal tyrosine phosphorylation of Src Y418 (Fig. 2) . Interestingly, treatment with the Met inhibitor did not detectably decrease Src tyrosine phosphorylation, and inhibition of Src with PP2, as evident by the loss of Y418 phosphorylation, did not significantly alter Met tyrosine phosphorylation (Fig. 2) . Thus, the basal Src activation observed in these gastric cancer cell lines appears independent of Met kinase activity. Importantly, levels of c-Cbl or Cbl-b protein did not increase upon inhibition of Src kinase and were only elevated following inhibition of Met kinase (Fig. 2) . Moreover, inhibition of both Met and Src kinases increased the amount of Cbl proteins to a level comparable, but not exceeding, that with Met inhibitor alone. Hence, together these data support that in these gastric cancer cell lines, Cbl protein levels are dependent on the kinase activation status of Met and not Src.
Transient overexpression of Met promotes loss of
Cbl-b -In order to elucidate the requirements through which Met promotes loss of Cbl in gastric cancer cell lines, a transient transfection and structure-function approach was undertaken. Met was initially expressed at increasing concentrations with either HA-tagged c-Cbl or Cbl-b (Fig. 3A) .
In HEK 293 cells, overexpression of Met protein alone is sufficient to activate the Met kinase ( Fig. 3A ) (36) , and constitutive phosphorylation of Met. Increasing levels of Met expression resulted in a significant decrease in Cbl-b protein levels, whereas c-Cbl protein levels were largely unaffected under these conditions (Fig. 3A) . Tpr-Met, the truncated, constitutively active, cytoplasmic variant of Met also induced a dramatic loss in Cbl-b protein upon transient co-expression (Fig. 3B) . As expected, the overexpression of either c-Cbl or Cbl-b promoted an efficient loss of total Met protein and a corresponding decrease in phosphoMet (pY1234/1235) levels (Fig. 3A) (27). However, neither c-Cbl nor Cbl-b overexpression promotes loss of Tpr-Met, as Tpr-Met lacks Y1003, the binding site for the Cbl TKB domain (27) (Fig. 3B) .
Quantitation of c-Cbl and Cbl-b mRNA levels in the absence and presence of Met show that Cbl-b mRNA levels are not decreased upon transient co-expression with Met ( Supplemental  Fig. 4A ). Thus, this supports our data in gastric cancer cell lines, demonstrating that decrease in Cbl protein levels in the presence of active Met protein is not due to alterations in the level mRNA. Co-expression of either c-Cbl or Cbl-b with increasing levels of EGFR or activated Src (Src Y527F) resulted in a decrease in both c-Cbl and Cbl-b protein levels (Fig. 4C-D) , corroborating previously published data (39, 41) . Since transient Met expression promoted a significant and consistent loss of Cbl-b protein levels, structure-function studies were carried out with Cbl-b.
Met-dependent Cbl-b loss requires Met kinase activity and intact Cbl-b TKB and RING domain
-As a means to validate the requirement for Met kinase activity in promoting Cbl loss, Met wildtype and a mutant unable to promote transfer of the γ-ATP (kinase-dead K1110A) constructs were expressed alone, or with HA-tagged Cbl-b. Co-expression of wild-type Met and Cbl-b resulted in loss of both Met and Cbl-b protein (Fig. 4A) . However, this loss was not observed upon co-expression of Met K1110A with Cbl-b (Fig. 4A) , demonstrating the dependency of Cbl protein loss on Met kinase activity.
To determine the regions or domains of Cbl-b required for Cbl-b loss, a panel of HAtagged Cbl-b mutants (Fig. 4B) consisting of wild-type Cbl-b, a Cbl-b unable to bind Met through its TKB domain (G298E), an E3 ligasedead mutant (Cbl-b C373A), and multiple truncation mutants that excise the UBA domain (Cbl-b ΔUBA), proline-rich regions and/or key tyrosine residues (Y665/Y709) (Cbl-b 1-483, 1-541, 1-603, 1-664, 1-821) were examined for their stability when expressed in HEK 293 cells alone, or with wild-type Met. With the exception of the G298E and C373A mutant, in the presence of Met, protein levels of each Cbl-b construct were decreased, as compared to their expression levels in the absence of Met (Fig. 4C) . Cbl-b G298E abrogates TKB function, uncoupling MetCbl-b direct interaction, and Cbl-b C373A, which lacks functional E3 ligase activity in the RING domain, do not exhibit protein loss upon coexpression with Met indicating a necessity for TKB and RING function in promoting Cbl-b loss downstream from Met (Fig. 4C) . In support of this, when c-Cbl or Cbl-b were transiently expressed in 293 cells with Met and FLAGtagged ubiquitin, increased ubiquitination of Cblb, as compared to c-Cbl, was observed, and this effect was enhanced upon treatment with the proteasome inhibitor, lactacystin, prior to cell lysis (Supplemental Fig. 5) . The low level of cCbl ubiquitination following transient transfection substantiates the lack of c-Cbl protein loss, when compared to Cbl-b, upon overexpression with Met.
Cbl-b is in part recruited to Met indirectly through the Grb2 adaptor protein (27). The requirement for indirect association of Met and Cbl-b (via Grb2) for Met-dependent Cbl-b loss was also assessed. The C-terminal half of Cbl-b contains six putative Grb2 binding sites (http://scansite.mit.edu). Three of these sites are absent in Cbl-b 1-664 and the remaining three sites were mutated through site-directed mutagenesis (Cbl-b 1-664 9PA) . This construct, as demonstrated through GST-Grb2 pull-down (Fig. 4F) , is dramatically impaired in its ability to bind Grb2, as compared to wild-type Cbl-b. Protein levels of Cbl-b 1-664 9PA decrease in the presence of Met (Fig. 4E) , demonstrating that recruitment of Grb2 is dispensable for Cbl-b protein loss. To our knowledge, this is the first demonstration of these three Grb2 binding sites on Cbl-b. Altogether, this demonstrates that the C-terminal UBA domain on Cbl-b, as well as the proline-rich regions and tyrosines 665 and 709 are dispensable for to Met-dependent Cbl-b protein loss after transient transfection. Furthermore, as Cbl-b ubiquitination was observed and Cbl-b E3 ligase activity is required, this data supports that Cbl-b loss may occur through self-ubiquitination. Supplemental Fig. 6A ). By 2 hours of HGF stimulation, Cbl-b levels decrease when compared to unstimulated control (Supplemental Fig. 5A ). To determine if Cbl-b protein was being degraded through the lysosome or proteasome, inhibitors for both (concanamycin and lactacystin, respectively) were used. Cells were pre-treated with concanamycin or lactacystin for 4 hours prior to HGF stimulation. Concanamycin addition did not affect Cbl-b loss with HGF stimulation, while the presence of lactacystin was able to partially rescue Cbl-b levels (Supplemental Fig. 6A ). In Snu-5 and KATO II cells, lactacystin treatment resulted in an increase in c-Cbl levels as shown in Fig. 5A -B.
Met-dependent Cbl loss requires proteasome activity -Basal activation of
Quantitation of three independent experiments demonstrates that upon Met inhibition, c-Cbl protein levels increase 2.5-fold (Fig. 5C ). The same trend was observed in Okajima and MKN45 cells (Supplemental Fig.  6B ). Altogether, this data implicates a role for the proteasome in c-Cbl degradation, downstream from kinase active Met.
Considering that c-Cbl protein levels are increased upon inhibition of the proteasome, we assessed whether c-Cbl is ubiquitinated under basal conditions in gastric cancer cells. To establish this, KATO II cells were treated overnight (16h) with Met inhibitor, followed by treatment with Lactacystin for 8h. Subsequent to cell lysis, c-Cbl proteins were immunoprecipitated under denaturing conditions, to uncouple associated proteins, and ubiquitination detected using anti-ubiquitin antibodies (P4D1 and antibodies raised to K48-linked poly ubiquitin (D9D5)).
c-Cbl is ubiquitinated in the presence of active Met which is diminished following inhibition of Met, even though c-Cbl protein levels are elevated (Fig. 5F-G) . The comparable patterns of total ubiquitin and K48-linked polyubiquitin indicate that c-Cbl is poly-ubiquitinated and contains K48-linked chains (Fig. 5F ). As K48-linked chains are thought to promote proteasomal degradation, and c-Cbl ubiquitination is most apparent where Met is active and following treatment with lactacystin ( Fig. 5F ), this supports that Met-activation promotes c-Cbl polyubiquitination and subsequent degradation by the proteasome.
In gastric cancer cells, c-Cbl coimmunoprecipitates with Met and is tyrosine phosphorylated, both of which are decreased in the presence of Met inhibitor and are hence dependent on Met kinase activity (Fig. 5E ). In comparison, while Cbl-b can coimmunoprecipitate with Met in gastric cancer cell lines, Cbl-b tyrosine phosphorylation was not observed (Supplemental Fig. 6C ). In support of the enhanced association of c-Cbl with Met, cCbl co-localizes with Met both at the membrane and in punctate structures in MKN45 gastric cancer cells (Supplemental Fig. 7B ). Moreover, we observe co-localization of c-Cbl (64%) protein with Met by immunofluorescence, as compared to only 34% of Cbl-b protein (Supplemental Fig. 7A) . Hence, the enhanced association of Met and c-Cbl compared to Cbl-b in gastric cancer cells as observed by immunofluorescence likely contributes to enhanced ubiquitination and decreased stability of c-Cbl over Cbl-b protein levels. (42)). Hence, to investigate whether Met-dependent Cbl loss in gastric cancer cell lines, augments the stability and/or signaling of other kinases, the stability of EGFR was assessed in MKN45 cells upon EGF stimulation in the presence or absence of Met inhibitor (Fig. 6A ). While stimulation with EGF promotes EGFR protein loss, EGFR loss is statistically significant only in the presence of the Met inhibitor, when Cbl levels are elevated and not in control cells (Fig. 6B) .
EGFR degradation and Cbl-recruitment is impaired in MET-amplified gastric cancer cell lines -Cbl proteins negatively regulate multiple receptor tyrosine kinases including EGFR (reviewed in
To establish whether the enhanced degradation of EGFR in MKN45 cells, in the presence of EGF and the Met inhibitor, corresponds with increased association between Cbl and EGFR, their ability to coimmunoprecipitate was investigated.
Under basal conditions where Met is active, c-Cbl coimmunoprecipitates with a phospho-protein corresponding to molecular weight of Met, that disappears upon treatment with the Met inhibitor (Fig. 6C) . Cbl-b also co-immunoprecipitates with active Met (Fig. 6D) . Interestingly, upon stimulation with EGF, phospho-EGFR predominantly co-immunoprecipitates with Cbl-b ( Fig. 6C and D) . Notably, this EGF-dependent association of Cbl-b and EGFR is significantly enhanced when Met kinase activity is inhibited (Fig. 6D) . c-Cbl also co-immunoprecipitates with EGFR following stimulation with EGF, and although this is enhanced following inhibition of Met, this is consistently less that with Cbl-b (Fig.  6C) . Hence under conditions where Met is inhibited and Cbl protein levels are increased, Cbl is able to more efficiently target EGFR for degradation due to enhanced association with EGFR and decreased competition for Cbl binding from Met.
DISCUSSION
Protein tyrosine kinases act as molecular switches to control a variety of cellular signals, and their dysregulation contributes to many human malignancies. Notably, members of the Cbl family can serve as negative regulators for many tyrosine kinases and loss of Cbl dependent negative regulation is recognized as a mechanism that contributes to tumorigenesis (43). Here we demonstrate Met-dependent loss of Cbl protein as a mechanism to decrease Cbl-mediated negative regulation of RTKs in human cancer. While other reports have detailed loss of Cbl protein downstream from EGFR and Src kinases (39, 41, 44) , this is the first report demonstrating Cbl protein loss dependent on an activated Met kinase in human tumors.
The mechanism of Cbl loss downstream from Met is dependent on an intact Cbl TKB domain and RING domain. This is distinct from Src-dependent Cbl loss, which occurs independently of the Cbl RING domain (Table 1 ) (39) . Furthermore, Src-dependent Cbl loss requires tyrosines Y700, Y731, and Y774 in the C-terminal half of Cbl (39, 45) , of which the equivalent tyrosines (Y665 and Y709) are dispensable for Met-dependent Cbl-b loss (Fig.  4) . In support of this, we demonstrate that Metdependent c-Cbl or Cbl-b loss in multiple gastric tumor cell lines is independent of Src kinase activity. In a similar manner to Met, Cbl-b loss downstream from the EGFR also requires both an intact Cbl TKB and RING domains and not Cterminal proline-rich or UBA regions (41) .
Inhibition of the proteasome rescues Cbl levels downstream from Met kinase. This supports the requirement for an intact Cbl E3 ligase function whereby Cbl is auto-ubiquitinated following Met activation. Consistent with this, cCbl ubiquitination is elevated in gastric cancer cell lines where Met is activated. Similarly ubiquitination of Cbl has been observed downstream from several activated kinases including EGFR, Src, and CSF-1 receptor (39, 41, 46) . Met kinase activity is required for Cbl loss (Fig. 1 & 4A) . Tyrosine phosphorylation of Cbl is required for activation of its E3 ligase (47, 48) , and mutants that either remove the tyrosine phosphorylation site in the linker region of Cbl, or promote loss of ligase activity are increasingly found in tumors (49) (50) (51) (52) (53) . Hence, the ubiquitination of Cbl, subsequent to constitutive Met kinase activation, may be a negative feedback mechanism regulating c-Cbl stability in human tumors. Other E3 proteins have been shown to self-ubiquitinate and target themselves for degradation, and regulation of Cbl activity, by mediating its stability, has been previously documented to occur (reviewed in (44) Constitutive Met activation, following amplification in gastric cancers, is not a result of an autocrine loop, as HGF mRNA is undetectable in these cell lines (10) . Moreover, sequencing of Met has not yet revealed the presence of known activating mutations in MKN45, Snu-5, and KATO II gastric cancer cell lines where MET is amplified (10) . Thus, the loss of Cbl protein and negative regulation of Met may be a contributing factor enhancing Met prolonged activation in the absence of ligand. Tpr-Met, an oncogenic Met variant, is the result of a genomic rearrangement, where a leucine zipper dimerization domain promotes enforced dimerization of the Met kinase in the absence of ligand, driving constitutive activation and phosphorylation (2, 55) .
However, another contributing mechanism to the transforming ability of TprMet is the uncoupling from Cbl-mediated negative regulation (31) .
Tpr-Met is cytoplasmically located, and lacks the juxtamembrane Y1003, and is thus unable to associate with Cbl, enter the endocytic pathway, and be efficiently degraded (31) . Restoration of the Cbl binding site, membrane localization and Cbl expression was found to be required for downregulation of Tpr-Met and suppression of transformation (31) . In murine models, wild-type or mutated Met (M1250T) under the MMTV promoter are weakly transforming (56) . However, mice expressing a Met receptor with both M1250T and Y1003F mutations, thereby diminishing the ability of Cbl to bind and ubiquitinate Met, exhibit a greater penetrance and a shorter latency (approximately 100 days less) (56) , demonstrating that the loss of Cbl-mediated negative regulation enhances Met oncogenic capabilities. Interestingly the human gastric cancer cell line Hs746T, expresses mutated Met receptor (Met Δexon14) that lacks the direct Cbl binding site (Y1003) in addition to amplification of MET (35) . In these cells, inhibition of constitutively active Met does not impact c-Cbl or Cbl-b protein levels (data not shown), supporting that Met-dependent Cbl loss requires association between the two proteins, and highlighting that selection can occur for alternative mechanisms that uncouple Met from Cbl. Moreover, in lung cancers where tested, over 80% of tumors with c-CBL genomic changes also exhibit mutations in either MET or EGFR (52) . Exogenous expression of c-Cbl in lung cancer cells can also inhibit tumor growth and metastasis in a xenograft mouse model (57) . Thus, together, this supports that the Metdependent loss of Cbl proteins exhibited in the four gastric cancer cell lines examined here (Okajima, MKN45, Snu-5, KATO II) would lead to enhanced dysregulation of MET and, potentially, other Cbl targets.
Notably in the four gastric cancer cell lines tested, Met-dependent suppression of Cbl levels, augments the stability of other Cbl target proteins, such as EGFR (Fig. 6 ). This has important implications for RTK crosstalk, whereby activation of Met can lead to tyrosine phosphorylation and activation of EGFR and vice versa (43). Hence, Met-dependent Cbl loss in gastric cancers thereby provides a mechanism through which Met activation can indirectly enhance EGFR signaling (Fig. 7) . Met may also promote EGFR stability by virtue of its overexpression, thereby sequestering Cbl away from EGFR. Thus, in these cancer cells, Met recruitment of Cbl and targeted downregulation may take advantage of a normal feedback mechanism regulating Cbl, creating a platform of activated RTKs that, together, contributes to potentiating oncogenic signaling. 
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